Fapon to Showcase AI-Engineered Enzymes at AMP 2026

SEATTLE, Nov. 10, 2026 /CourierPR/ -- The Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo, which runs November 10 to 14 at the Seattle Convention Center, is set to feature Fapon, a leading life sciences organization. At Booth 1905, Fapon will showcase its latest innovations in molecular diagnostics, including AI-engineered enzymes and end-to-end RNA work flows.

Fapon will present its AI-engineered enzymes, such as ProPrime II Taq DNA Polymerase and MeloScript III WS Reverse Transcriptase, at the conference. ProPrime II Taq DNA Polymerase is a second-generation antibody hot-start polymerase that can amplify reliably in the presence of 5% whole blood and nine common PCR inhibitors, including hemoglobin, Trizol, SDS, guanidine hydrochloride, and EDTA, and maintains strong performance at low template concentrations. It is designed for multiplexed qPCR panels and near-patient testing, where speed and tolerance to crude samples determine throughput.

MeloScript III WS Reverse Transcriptase is a third-generation hot-start RT for one-step RT-qPCR. It delivers about 64% blocking efficiency after one hour at 37°C and maintains reverse transcription performance after 10 minutes at 52 to 64°C. The glycerol-free, lyophilization-ready format and stability across 25 freeze-thaw cycles make it suitable for lyophilized reagents and near-patient assay formats.

Fapon will also highlight its RNA library prep portfolio, which includes the NK081 Poly(A) mRNA Magnetic Isolation Module, which removes 95% or more of rRNA in under 40 minutes, with residual rRNA as low as 0.15% across 12 validated species. The company's VeloScript I (MD03049) is engineered for single-cell and picogram-level inputs, synthesizing full-length cDNA up to 15 kb at 55°C without temperature optimization, and accepting 10 pg to 10 μg of RNA. It also maintains performance in the presence of common extraction inhibitors such as ethanol and salts, a practical requirement when RNA is recovered from limited or challenging samples.

The session will explore how AI-powered enzyme engineering can advance performance across qPCR, RT-qPCR, NGS, and isothermal amplification, connecting technological innovation with real-world molecular diagnostic applications.

This approach significantly accelerates novel biomarker/target discovery and translation. Fapon has established an integrated business structure that combines AI-powered innovative discovery, one-stop diagnostic solutions, and novel therapies. Its products and services have covered the full spectrum of health management across the entire lifecycle, and accelerated the development of precision medicine. Fapon's products and services have reached over 70 countries and regions, and more than 2,500 partners worldwide. Leveraging its AI-driven, diagnostics and therapeutics closed-loop innovation platforms, Fapon connects healthcare resources across the globe, continuously contributing to a healthier and better future for all.